CASE REPORT article
Front. Med.
Sec. Precision Medicine
A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation
Provisionally accepted
- Yunnan Cancer Hospital, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
For advanced or metastatic non-small cell lung cancer (NSCLC) with actionable gene mutations, first-line targeted therapy significantly prolongs survival compared to chemotherapy and immunotherapy. Perioperative targeted therapy has achieved great improvement in early and locally advanced-stage NSCLC patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. However, there have been few reports of neoadjuvant treatment in patients with non-small cell lung cancer with rare mutations (such as the BRAF V600E mutation). In this report, we present a case of inoperable stage IIIA lung adenocarcinoma with a BRAF V600E mutation then underwent radical lung cancer surgery following neoadjuvant targeted therapy. The postoperative pathology review revealed a pathological complete response (pCR). This case illustrates that BRAF and MEK inhibitor therapy may represent a viable option for neoadjuvant therapy in locally advanced BRAF V600E mutant NSCLC.
Keywords: BRAF V600E mutation, dabrafenib, trametinib, NSCLC, Neoadjuvant Therapy
Received: 11 Jul 2025; Accepted: 24 Nov 2025.
Copyright: © 2025 Peng, Qu, Cai, Yang, Dong, Li, Ran and LUO. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chunxiang LUO, luochunxiang@kmmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.